Tissue angiotensin II in the regulation of inflammatory and fibrogenic components of repair in the rat heart

Journal of Laboratory and Clinical Medicine

Volumn 143, Issue 1, 2004, Pages 41-51

  Sun, Yao ^a   Zhang, Jiakun ^b   Lu, Li ^b   Bedigian, Martin P ^b   Robinson, Antwon D ^b   Weber, Karl T ^b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; COLLAGEN TYPE 1; DIPEPTIDYL CARBOXYPEPTIDASE; FIBRILLAR COLLAGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; RENIN; SODIUM CHLORIDE; TRANSCRIPTION FACTOR RELA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; VALSARTAN;

ANGIOTENSIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENUATION; AUTORADIOGRAPHY; BINDING AFFINITY; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CELL INFILTRATION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY FIBROSIS; CUFF; DIETARY INTAKE; DRUG EFFECT; ENZYME BINDING; EXPERIMENTAL MODEL; GENE EXPRESSION; HEART INJURY; HEART LEFT VENTRICLE; HEART RIGHT VENTRICLE; HYPERTENSION; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INFLAMMATORY CELL; ISOLATED HEART; MALE; MEDIATOR RELEASE; MICROSCOPY; MYOCARDITIS; MYOFIBROBLAST; NONHUMAN; PLASMA RENIN ACTIVITY; QUANTITATIVE ANALYSIS; RAT; SCAR FORMATION; TISSUE INJURY; TISSUE REPAIR; VASCULAR FIBROSIS;

EID: 0742269624     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lab.2003.07.004     Document Type: Article

References (61)

1. Weber KT. Extracellular matrix remodeling in heart failure. A role for de novo angiotensin II generation. Circulation 1997;96: 4065-82.
2. Weber KT. Angiotensin II and connective tissue: homeostasis and reciprocal regulation. Regul Pept 1999;82:1-17.
3. Sun Y, Weber KT. Angiotensin II receptor binding following myocardial infarction in the rat. Cardiovasc Res 1994;28:1623-8.
4. Yamagishi H, Kim S, Nishikimi T, Takeuchi K, Takeda T. Contribution of cardiac renin-angiotensin system to ventricular remodelling in myocardial-infarcted rats. J Mol Cell Cardiol 1993;25:1369-80.
5. Frustaci A, Kajstura J, Chimenti C, Jakoniuk I, Leri A, Maseri A, et al. Myocardial cell death in human diabetes. Circ Res 2000; 87:1123-32.
6. Sun Y, Cleutjens JPM, Diaz-Arias AA, Weber KT. Cardiac angiotensin converting enzyme and myocardial fibrosis in the rat. Cardiovasc Res 1994;28:1423-32.
7. Ou R, Sun Y, Ganjam VK, Weber KT. In situ production of angiotensin II by fibrosed rat pericardium. J Mol Cell Cardiol 1996;28:1319-27.
8. Diet F, Pratt RE, Berry GJ, Momose N, Gibbons GH, Dzau VJ. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation 1996;94:2756-67.
9. 2 receptor-mediated P-selectin upregulation. Circulation 2000;102:2118-23.
10. Border WA, Noble NA. Transforming growth factor α in tissue fibrosis. N Engl J Med 1994;331:1286-92.
11. Morrissey JJ, Ishidoya S, McCracken R, Klahr S. The effect of ACE inhibitors on the expression of matrix genes and the role of p53 and p21 (WAF1) in experimental renal fibrosis. Kidney Int 1996;49(suppl 54):S83-7.
12. Sun Y, Weber KT. Angiotensin-converting enzyme and wound healing in diverse tissues of the rat. J Lab Clin Med 1996;127: 94-101.
13. 1 and repair in the infarcted heart. J Mol Cell Cardiol 1998;30:1559-69.
14. Sun Y, Ratajska A, Weber KT. Inhibition of angiotensin-converting enzyme and attenuation of myocardial fibrosis by lisinopril in rats receiving angiotensin II. J Lab Clin Med 1995;126: 95-101.
15. van Krimpen C, Schoemaker RG, Cleutjens JPM, Smits JFM, Struyker-Boudier HAJ, Bosman FT, et al. Angiotensin I converting enzyme inhibitors and cardiac remodeling. Basic Res Cardiol 1991;86(suppl 1):149-55.
16. Smits JFM, van Krimpen C, Schoemaker RG, Cleutjens JPM, Daemen MJAP. Angiotensin II receptor blockade after myocardial infarction in rats: effects on hemodynamics, myocardial DNA synthesis, and interstitial collagen content. J Cardiovasc Pharmacol 1992;20:772-8.
17. 1 and matrix proteins in cyclosporine nephropathy. Kidney Int 1997;52:660-73.
18. de Lannoy LM, Danser AH, van Kats JP, Schoemaker RG, Saxena PR, Schalekamp MA. Renin-angiotensin system components in the interstitial fluid of the isolated perfused rat heart. Local production of angiotensin I. Hypertension 1997;29:1240-51.
19. Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT. Remodeling of the rat right and left ventricle in experimental hypertension. Circ Res 1990;67:1355-64.
20. 1 expression. Hypertension 1994;23:587-92.
21. Selye H, Hall CE. Pathologic changes induced in various species by overdosage with desoxycorticosterone. Arch Pathol 1943;36: 19-31.
22. Sun Y, Ramires FJA, Weber KT. Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion. Cardiovasc Res 1997;35:138-47.
23. Brilla CG, Weber KT. Mineralocorticoid excess, dietary sodium and myocardial fibrosis. J Lab Clin Med 1992;120:893-901.
24. Brilla CG, Weber KT. Reactive and reparative myocardial fibrosis in arterial hypertension in the rat Cardiovasc Res 1992;26: 671-7.
25. Darrow DC, Miller HC. The production of cardiac lesions by repeated injections of desoxycorticosterone acetate. J Clin Invest 1942;21:601-11.
26. Campbell SE, Janicki JS, Weber KT. Temporal differences in fibroblast proliferation and phenotype expression in response to chronic administration of angiotensin II or aldosterone. J Mol Cell Cardiol 1995;27:1545-60.
27. Brilla CG, Matsubara LS, Weber KT. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol 1993;25:563-75.
28. Sun Y, Zhang J, Zhang JQ, Ramires FJA. Local angiotensin II and transforming growth factor-beta1 in renal fibrosis of rats. Hypertension 2000;35:1078-84.
29. 125I-labelled MK351A. Clin Exp Pharmacol Physiol 1984;11:431-5.
30. Muller DN, Dechend R, Mervaala EM, Park JK, Schmidt F, Fiebeler A, et al. NF-κB inhibition ameliorates angiotensin II-induced inflammatory damage in rats. Hypertension 2000;35(1 Pt 2):193-201.
31. Sun Y, Ratajska A, Zhou G, Weber KT. Angiotensin converting enzyme and myocardial fibrosis in the rat receiving angiotensin II or aldosterone. J Lab Clin Med 1993;122:395-403.
32. Loskutoff DJ, Quigley JP. PAI-1, fibrosis, and the elusive provisional fibrin matrix. J Clin Invest 2000;106:1441-3.
33. Pueyo ME, Gonzalez W, Nicoletti A, Savoie F, Arnal JF, Michel JB. Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-KB activation induced by intracellular oxidative stress. Arterioscler Thromb Vase Biol 2000;20: 645-51.
34. Aird WC, Edelberg JM, Weiler-Guettler H, Simmons WW, Smith TW, Rosenberg RD. Vascular bed-specific expression of an endothelial cell gene is programmed by the tissue microenvironment. J Cell Biol 1997;138:1117-24.
35. Singal PK, Khaper N, Farahmand F, Bello-Klein A. Oxidative stress in congestive heart failure. Curr Cardiol Rep 2000;2:206-11.
36. Mann DL. Tumor necrosis factor and viral myocarditis: the fine line between innate and inappropriate immune responses in the heart. Circulation 2001;103:626-9.
37. Anker SD, Chua TP, Ponikowski P, Harrington D, Swan JW, Kox WJ, et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation 1997;96:526-34.
38. Testa M, Yeh M, Lee P, Fanelli R, Loperfido F, Berman JW, LeJemtel TH. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J Am Coll Cardiol 1996;28:964-71.
39. Khaper N, Singal PK. Modulation of oxidative stress by a selective inhibition of angiotensin II type 1 receptors in MI rats. J Am Coll Cardiol 2001;37:1461-6.
40. Bozkurt B, Kribbs SB, Clubb FJ Jr, Michael LH, Didenko VV, Hornsby PJ, Seta Y, et al. Pathophysiologically relevant concentrations of tumor necrosis factor-α promote progressive left ventricular dysfunction and remodeling in rats. Circulation 1998; 97:1382-91.
41. Nicoletti A, Michel J-B. Cardiac fibrosis and inflammation: interaction with hemodynamic and hormonal factors. Cardiovasc Res 1999;41:532-43.
42. Robert V, Van Thiem N, Cheav SL, Mouas C, Swynghedauw B, Delcayre C. Increased cardiac types I and III collagen mRNAs in aldosterone-salt hypertension. Hypertension 1994;24:30-6.
43. Young M, Fullerton M, Dilley R, Funder J. Mineralocorticoids, hypertension, and cardiac fibrosis. J Clin Invest 1994;93:2578-83.
44. Young M, Head G, Funder J. Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. Am J Physiol 1995; 269:E657-62.
45. Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT. Aldosterone-induced inflammation in the rat heart. Role of oxidative stress. Am J Pathol 2002;161:1773-81.
46. Somers MJ, Mavromatis K, Galis ZS, Harrison DG. Vascular Superoxide production and vasomotor function in hypertension induced by deoxycorticosterone acetate-salt. Circulation 2000; 101:1722-8.
47. Beswick RA, Zhang H, Marable D, Catravas JD, Hill WD, Webb RC. Long-term antioxidant administration attenuates mineralocorticoid hypertension and renal inflammatory response. Hypertension 2001;37(2 Part 2):781-6.
48. Pagano PJ, Clark JK, Cifuentes-Pagano ME, Clark SM, Callis GM, Quinn MT. Localization of a constitutively active, phagocyte-like NADPH oxidase in rabbit aortic adventitia: enhancement by angiotensin II. Proc Natl Acad Sci U S A 1997;94: 14483-8.
49. Mohazzab KM, Kaminski PM, Wolin MS. NADH oxidoreductase is a major source of superoxide anion in bovine coronary artery endothelium. Am J Physiol 1994;266:H2568-72.
50. Gerling IC, Sun Y, Ahokas RA, Wodi LA, Bhattacharya SK, Warrington KJ, et al. Aldosteronism. An immunostimulatory state precedes the proinflammatory/fibrogenic cardiac phenotype. Am J Physiol 2003; in press.
51. Swei A, Lacy F, DeLano FA, Schmid-Schonbein GW. Oxidative stress in the Dahl hypertensive rat. Hypertension 1997;30:1628-33.
52. Laursen JB, Rajagopalan S, Galis Z, Tarpey M, Freeman BA, Harrison DG. Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. Circulation 1997;95: 588-93.
53. Swei A, Lacy F, Delano FA, Parks DA, Schmid-Schonbein GW. A mechanism of oxygen free radical production in the Dahl hypertensive rat. Microcirculation 1999;6:179-87.
54. Hahn AWA, Jonas U, Bühler FR, Resink TJ. Activation of human peripheral monocytes by angiotensin II. FEBS Lett 1994; 347:178-80.
55. Iwai N, Inagami T, Ohmichi N, Kinoshita M. Renin is expressed in rat macrophage/monocyte cells. Hypertension 1996;27:399-403.
56. Katwa LC, Campbell SE, Tyagi SC, Lee SJ, Cicila GT, Weber KT. Cultured myofibroblasts generate angiotensin peptides de novo. J Mol Cell Cardiol 1997;29:1375-86.
57. Rousseau-Plasse A, Lenfant M, Potier P. Catabolism of the hemoregulatory peptide W-Acetyl-Ser-Asp-Lys-Pro: a new insight into the physiological role of the angiotensin-I-converting enzyme W-active site. Bioorg Med Chem 1996;4:1113-9.
58. Challah M, Nicoletti A, Arnal JF, Philippe M, Laboulandine I, Allegrini J, et al. Cardiac angiotensin converting enzyme over-production indicates interstitial activation in renovascular hypertension. Cardiovasc Res 1995;30:231-9.
59. 1 receptor subtype as a cardiac target of aldosterone. Role in aldosterone-salt-induced fibrosis. Hypertension 1999;33:981-6.
60. Schiffrin EL, Gutkowska J, Genest J. Effect of angiotensin II and deoxycorticosterone infusion on vascular angiotensin II receptors in rats. Am J Physiol 1984;246:H608-14.
61. Schiffrin EL, Franks DJ, Gutkowska J. Effect of aldosterone on vascular angiotensin II receptors in the rat. Can J Physiol Pharmacol 1985;63:1522-7.